Inactive Instrument
Pathfinder Cell Therapy, Inc. Share Price Other OTC
Stocks
PFND
US70319A1060
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 2.07M 1.82M 1.69M 1.55M 2.92M 198M 2.96M 20.12M 7.86M 97.94M 7.76M 7.6M 338M | P/E 2013 |
-5.48x | P/E 2014 | -0.38x |
|---|---|---|---|---|---|
| Enterprise Value | 7.03M 6.18M 5.75M 5.28M 9.91M 674M 10.04M 68.33M 26.69M 333M 26.37M 25.8M 1.15B | EV / Sales 2013 |
246,023,185x | EV / Sales 2014 | - |
| Free-Float |
100% | Yield 2013 * |
-
| Yield 2014 | - |
| 1 day | -4.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Rick Franklin
CEO | Chief Executive Officer | 80 | 22/09/2011 |
John Benson
DFI | Director of Finance/CFO | 64 | 28/09/2011 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.71% | -13.83% | - | - | 667 | ||
| -0.29% | -0.96% | -1.17% | +10.70% | 47.74B | ||
| -0.61% | +4.26% | +396.16% | +647.20% | 39.98B | ||
| 0.00% | +4.93% | +11.81% | +55.56% | 36.23B | ||
| +2.48% | +4.57% | +7.05% | -5.05% | 35.59B | ||
| +0.62% | +3.53% | +5.41% | +42.19% | 27.91B | ||
| -0.17% | +0.66% | - | - | 16.71B | ||
| -2.00% | +11.64% | +31.71% | +136.81% | 16.45B | ||
| +0.57% | -3.36% | +2.90% | +8.02% | 13.21B | ||
| +1.82% | +1.56% | -9.75% | -30.15% | 12.93B | ||
| Average | +0.66% | +2.77% | +55.52% | +108.16% | 27.42B | |
| Weighted average by Cap. | +1.36% | +2.94% | +74.11% | +136.34% |
| 2013 | 2014 | |
|---|---|---|
| Net sales | 0.05 0.05 0.04 0.04 0.08 5.18 0.08 0.53 0.21 2.56 0.2 0.2 8.84 | - |
| Net income | -1.7M -1.5M -1.4M -1.28M -2.41M -164M -2.44M -16.58M -6.48M -80.74M -6.4M -6.26M -279M | -1.39M -1.23M -1.14M -1.05M -1.97M -134M -1.99M -13.56M -5.3M -66.01M -5.23M -5.12M -228M |
| Net Debt | 3.94M 3.47M 3.23M 2.96M 5.57M 378M 5.64M 38.37M 14.99M 187M 14.81M 14.49M 646M | 4.96M 4.36M 4.06M 3.73M 7M 475M 7.09M 48.22M 18.83M 235M 18.61M 18.21M 811M |
Employees
-
















